Whereas current cell culture systems typically yield fewer than 20 population doublings before the cells senesce, epithelial stem cells derived from many tissue types can be propagated more than a trillion-fold in Epix.
The Epix expanded cells are genetically stable, are not tumorigenic, and can be readily differentiated into tissue-specific phenotypes even after extensive expansion.
Stemcell is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research.
The company offers over 2500 products designed to support the basic to translational research continuum.
Propagenix is applying its proprietary technologies to internal and partnered cell therapy programs. The company's technology platform has proven ability for propagating tissue-resident epithelial stem cells of diverse tissue origins with unparalleled production efficiency, reliable safety, and predictable in vivo functionality.
In addition to cell therapeutics, Propagenix's technology addresses key bottlenecks in using primary cell models for drug discovery and toxicology, as well as creating new possibilities for use of patient-specific samples for precision medicine applications in oncology and respiratory disease.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval